Eli Lilly Slams 'Startling' Teva Brief In Alimta Patent Fight
Eli Lilly and Co. on Wednesday criticized as "startling" Teva Parenteral Medicines Inc.'s post-trial brief in a fight over whether Teva's labeling on a generic version of the cancer drug Alimta...To view the full article, register now.
Already a subscriber? Click here to view full article